Professor Junmin Li: Exploration and Clinical Practice of Umbilical Cord Blood Therapy in Elderly Patients with Acute Myeloid Leukemia

Professor Junmin Li: Exploration and Clinical Practice of Umbilical Cord Blood Therapy in Elderly Patients with Acute Myeloid Leukemia

In March, as spring brings clarity and renewal to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was convened from March 27 to 28, 2026, marking the 25th anniversary of the Hematology and Immunology Branch of the Chinese Society of Immunology.
Professor Zhenyu Yan: Seven Transformations in the Comprehensive Management of Hemophilia in China — From Survival to Functional Cure

Professor Zhenyu Yan: Seven Transformations in the Comprehensive Management of Hemophilia in China — From Survival to Functional Cure

In March, as spring breathes new life into Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, organized by the Hematology and Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was successfully convened from March 27 to 28, 2026. During the meeting, Professor Zhenyu Yan from the Affiliated Hospital of North China University of Science and Technology delivered a keynote lecture entitled “Seven Transformations in the Comprehensive Diagnosis and Management of Hemophilia in China.”
Professor Gang Zhu: Prevention and Treatment of Urologic Tumors — Early Screening Is Key, Personalized Care Enhances Patient Experience

Professor Gang Zhu: Prevention and Treatment of Urologic Tumors — Early Screening Is Key, Personalized Care Enhances Patient Experience

With the aging population and changes in lifestyle in China, the incidence of urologic cancers has been steadily increasing. Oncology Frontier – UroStream invited Professor Gang Zhu from Beijing United Family Hospital to discuss prevention strategies and personalized medical care in urologic oncology. Drawing from clinical practice, he emphasized the importance of early screening and diagnosis, as well as the unique features of international-standard medical services.
ASCO GU Key Opinion Leaders | Michiel van der Heijden: ADC + Immunotherapy Reshapes Urothelial Carcinoma Treatment, Opening New Paths for Bladder Preservation and Personalized Care

ASCO GU Key Opinion Leaders | Michiel van der Heijden: ADC + Immunotherapy Reshapes Urothelial Carcinoma Treatment, Opening New Paths for Bladder Preservation and Personalized Care

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), one of the world’s most prestigious meetings in genitourinary oncology, multiple landmark studies were presented that are reshaping clinical practice. Among them, advances in urothelial carcinoma (UC) stood out prominently.
ASCO GU Insights | Haige Chen: Breakthroughs in Bladder Cancer and the New Era of Precision Treatment

ASCO GU Insights | Haige Chen: Breakthroughs in Bladder Cancer and the New Era of Precision Treatment

At the 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026), held in San Francisco, leading experts from around the world gathered to present cutting-edge advances in urothelial carcinoma (UC). Key themes included antibody–drug conjugate (ADC) plus immunotherapy strategies for bladder preservation, clinical translation of liquid biopsy technologies, and deeper exploration of tumor molecular mechanisms.
EAU26 Afternoon Dialogue | Xuesong Li: ADC Plus Radiotherapy in the Perioperative Setting Breaks Therapeutic Barriers and Opens a New Era of Precision Treatment for UTUC

EAU26 Afternoon Dialogue | Xuesong Li: ADC Plus Radiotherapy in the Perioperative Setting Breaks Therapeutic Barriers and Opens a New Era of Precision Treatment for UTUC

At the 2026 European Association of Urology Congress (EAU26), held in London, major advances in urologic oncology were presented. Among them, the work of Professor Xuesong Li’s team from Peking University First Hospital attracted considerable attention. The team not only contributed important achievements in upper urinary tract reconstruction but also presented a phase II clinical study of disitamab vedotin combined with radiotherapy for upper tract urothelial carcinoma (UTUC), offering a promising new treatment option.
EAU 2026 Afternoon Dialogue | Fred Saad: Frontiers in Prostate Cancer Treatment and the Future Landscape

EAU 2026 Afternoon Dialogue | Fred Saad: Frontiers in Prostate Cancer Treatment and the Future Landscape

At the 2026 European Association of Urology (EAU) Annual Congress held in London, leading experts from around the world gathered to discuss the latest advances and evolving clinical practices in genitourinary oncology. During the meeting, Oncology Frontier had the privilege of interviewing Professor Fred Saad from the Centre Hospitalier de l’Université de Montréal, who shared key insights into his team’s latest research, major breakthroughs in prostate cancer, and future therapeutic directions.
EBMT 2026 China Voice | Dr. Yishan Ye: Rethinking Donor Selection — Haploidentical Transplantation May Be the Optimal Choice for MRD-Positive AML

EBMT 2026 China Voice | Dr. Yishan Ye: Rethinking Donor Selection — Haploidentical Transplantation May Be the Optimal Choice for MRD-Positive AML

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.